AstraZeneca

Lindsay Hoyle Excerpts

Monday 3rd February 2025 Commons Chamber

[Chris Bryant]

What utter nonsense. We endured 14 years of growth that even the shadow Minister’s own Back Benchers used to describe as anaemic and feeble. Average growth under Tory Governments is 1.2%; average growth under Labour Governments is 2.4%. We are far more likely to secure growth in the British economy under a Labour Government.

The shadow Minister simply did not listen to what I had to say. The Conservatives sat on this so-called deal with AstraZeneca for four years. The process started in 2020, and it is interesting what was announced to the House and what was actually announced in the paperwork. In the House, the then Chancellor said that AstraZeneca had announced plans to invest to

“fund the building of a vaccine manufacturing hub in Speke in Liverpool.”—[Official Report, 6 March 2024; Vol. 746, c. 845.]

He did not make any mention in the Chamber of the money that was needed from his Department to be able to pay for it. The paperwork that attended that announcement stated:

“AstraZeneca’s investment decision is contingent upon mutual agreement with the UK Government and third parties, and successful completion of regulatory processes.”

That was absolutely typical of the previous Government: they thought that when they had announced something it had come to pass, but due diligence is needed to ensure the best possible financial advantage for the British taxpayer.

We have seen clearly that AstraZeneca’s original intention last year was to deliver £150 million-worth of R&D, but then it decided to cut that to something like £90 million-worth. That was its decision, based on its own investment decisions, and we as a Government had to assess whether £90 million from the UK—as supposedly promised by the previous Chancellor—was the right amount of money to put into the pot, or whether it was better to offer slightly less. Unfortunately, at the end of that process AstraZeneca decided that it would not proceed.

Let me make it absolutely clear to the hon. Member that this is the best country in the world in which to invest in the private sector. Some £63 billion of investment was secured at the growth summit last year, and £14 billion—[Interruption.]

[Mr Speaker]

Order. The shadow Secretary of State for Wales, the hon. Member for East Grinstead and Uckfield (Mims Davies), keeps pushing it a little bit. I think we should hear no more of that.

[Chris Bryant]

Thank you, Mr Speaker. And £14 billion was secured following the announcement of our artificial intelligence opportunities plan. We have cut the rate of corporation tax to 25%, which is the lowest in the G7. We are creating a pension mega-fund to be able to invest further. According to PricewaterhouseCoopers’ last CEO survey, we are, for the first time ever, the second-best place in the world to invest in the Government, and that is because we have a Labour Government, not a Conservative reject.

[Mr Speaker]

I call the Chair of the Science, Innovation and Technology Committee.

[Chi Onwurah (Newcastle upon Tyne Central and West) (Lab)]

The UK Government are committed to growing the economy through increased R&D and advanced manufacturing. AstraZeneca tell us that it is committed to investing in the UK, which is where it is headquartered and where one of its largest customers—the NHS—is based. It is like hearing that two people are madly in love with each other, yet the wedding is off. I look forward to the Minister of State for Science explaining the background to this to the Select Committee when he appears before us next week.

In the meantime, will the Minister confirm that the UK is committed to incentivising R&D investment? Will he set out the mix of R&D and manufacturing investment agreed to by AstraZeneca under the last Government, and to which it was committed when it dropped the deal? Finally, the deal, as well as growing the economy, would have made our pandemic supply chain more resilient by reducing our dependence on mRNA vaccines. Will he set out how he intends to address that?

[Chris Bryant]

It is good to hear from the Chair of the Select Committee. I want to make it absolutely clear that AstraZeneca is not leaving—people are not losing their jobs because of this decision. There are still 10,000 people employed by AstraZeneca in the UK and, for that matter, it is proceeding with its nasal-based flu vaccine for children, just in a different way. All of that is important.

My hon. Friend asked about the precise details of the R&D mix that was part of the investment. As I said, it was to have been £150 million of investment. AstraZeneca decided to cut that to £90 million, which is why the contribution that the previous Chancellor had suggested of £90 million into that pot simply did not add up for the UK taxpayer, which is why we came to that set of decisions. However, she is absolutely right that we are fundamentally committed to the life sciences sector for the saving of life, for making sure that we have an NHS that can really deliver for people, and because we want to have valuable jobs that we do better in this country than anywhere else in the world.

[Mr Speaker]

I call the Liberal Democrat spokesperson.

[Victoria Collins (Harpenden and Berkhamsted) (LD)]

This news makes for yet another disappointing day for the UK’s investment landscape. We could be a global leader in innovation, but ever since the previous Conservative Government’s scrapping of the industrial strategy businesses have been left with uncertainty. The life sciences sector is vital not just for economic growth, but for our health and technological innovation. It contributes over £43 billion to the UK economy, supports thousands of highly skilled jobs and drives breakthroughs in medicine and healthcare, yet in conversations that I have had with businesses, I have heard time and again how the UK’s fragmented approach to investment is holding them back. That is why I have highlighted those concerns in previous questions to the Secretary of State.

The Government have promised to publish “Invest 2035” this spring, but right now companies still have no detail on what support will be available and when. Without urgent action, we risk more world-leading firms following AstraZeneca’s lead and taking their investments elsewhere. Will the Minister please confirm exactly when the final Invest 2035 strategy will be published? The Government said that the decision was based on value for money, so will the Minister and the Secretary of State also publish the impact assessment, so that we can see for ourselves?